Drug intelligence / Profile preview

Atrogi muscular wasting compound

Development stage: Preclinical
Lead developer: Atrogi
Modality: Small Molecules
Administration: Oral

Overview

Atrogi's unnamed muscular wasting compound is a preclinical-stage small molecule designed to treat muscle-wasting conditions such as cachexia or sarcopenia. It functions as a selective agonist of the β2-adrenergic receptor, utilizing Atrogi's proprietary β2-stimulation technology platform. This platform aims to develop compounds that trigger specific intracellular signaling pathways to promote muscle protein synthesis and prevent degradation, while avoiding the typical side effects associated with traditional β2-adrenoceptor ligands. The candidate is currently in the lead selection phase of development.

Other names: Atrogi-β2-adrenergic receptor-small molecule-muscular wastingUnnamed muscular wasting compound

Targets

ADRB3 (β3)ADRB2 (β2)

Beyond the preview

Go deeper on Atrogi muscular wasting compound.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atrogi muscular wasting compound.

Explore the full profile